Dr. Reddy’s forays into HRT with acquisition of 2 brands from U.K. firm

Dr. Reddy’s Laboratories has acquired the trademarks of specialty brands Progynova and Cyclo-Progynova and related assets for India from the U.K.-headquartered Mercury Pharma Group.

The acquisition strengthens its gynaecology portfolio and marks entry into the hormone replacement therapy (HRT) segment, Dr. Reddy’s said on Wednesday.

Progynova (estradiol valerate) is an oral HRT indicated for treatment of estrogen deficiency symptoms and for prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined HRT indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components.

Progynova is the number one brand in the Estradiol represented pharmaceutical market, with strong physician equity and brand recall in India. The brand recorded sales of ₹100 crore, the Hyderabad-headquartered drugmaker said, citing IQVIA MAT December 2025 numbers.

“The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India,” CEO-Branded Markets (India and Emerging Markets) M.V. Ramana said.